Physician profile
Allison E Ogle
NPI 1447838610
$825.84
in general payments reported to CMS, 2019-2025
15 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $326 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135.77 | 2025 | |
| Glaxosmithkline, LLC. | $81.75 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $77.58 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $67.32 | 2024-2025 | |
| Axsome Therapeutics, INC. | $63.68 | 2025 | Symbravo |
| Novo Nordisk INC | $61.60 | 2025 | Rybelsus, Ozempic, Wegovy |
| Antares Pharma, INC. | $60.21 | 2024 | Xyosted |
| Exact Sciences Corporation | $49.67 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $45.13 | 2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $43.28 | 2024-2025 | Rexulti |
| Cequr Corporation | $41.55 | 2025 | Cequr Simplicity |
| Globus Medical, INC. | $35.75 | 2025 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $33.69 | 2024 | |
| Merck Sharp & Dohme LLC | $14.78 | 2024 | Gardasil, Gardasil 9 |
| Astrazeneca Pharmaceuticals Lp | $14.08 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Ogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.